Form 4: Plus Therapeutics CFO Acquires Stock Options

Andrew Sims, Chief Financial Officer of Plus Therapeutics, Inc., acquired stock options and restricted stock units on May 14, 2026.

Summary

• Andrew John Hugh MacIntyre Sims, the Chief Financial Officer of Plus Therapeutics, Inc., reported a transaction on May 14, 2026.
• Sims acquired 3,443 Restricted Stock Units (RSUs) with a reported price of $0.
• He also acquired 3,443 stock options with an exercise price of $5.76.
• Following these transactions, Sims beneficially owns 30,055 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily reports routine insider transactions rather than significant financial performance or strategic shifts.

Positives

• The Chief Financial Officer's acquisition of stock options and RSUs may indicate confidence in the company's future prospects.
• The acquisition of stock options at a price of $5.76 suggests a potential upside for the company's stock price from the current level.

Negatives

• The RSUs were awarded with a $0 price, which is standard for equity compensation but does not represent an out-of-pocket investment by the executive.
• The filing does not provide details on the performance or financial health of the company, only executive transactions.

Risks

• The vesting schedule for RSUs and stock options means that the full benefit is realized over time, contingent on continued employment and company performance.
• The value of the stock options is directly tied to the future stock price of Plus Therapeutics, which is subject to market volatility and company-specific risks.

Future Outlook

The vesting of RSUs and stock options over time, as detailed in the explanations, indicates a forward-looking incentive structure tied to continued employment and potential stock price appreciation.

Industry Context

StockSavvy.ai notes that insider transactions, such as the acquisition of stock options and RSUs by a Chief Financial Officer, are common in the biotechnology and pharmaceutical sectors as a means to attract and retain key talent and align executive interests with shareholder value.

Stakeholder Impact

• Shareholders: The acquisition of options by the CFO could be interpreted as a positive signal of management's belief in future stock performance, though it is a standard compensation practice.
• Employees: The RSU and option grants are part of the executive compensation structure, aligning management with company performance.
• Creditors: No direct impact on creditors is indicated by this filing.

Next Steps

• Vesting of Restricted Stock Units over twelve quarters, commencing July 1, 2026.
• Vesting of stock options over four years, with monthly increments.
• Potential exercise of stock options if the stock price exceeds the $5.76 exercise price.

Key Dates

Keywords

Form 4, SEC Filing, Plus Therapeutics, PSTV, Andrew Sims, Chief Financial Officer, Stock Options, Restricted Stock Units, Beneficial Ownership, Insider Trading